Publications

 


  • 268. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.

    Vis AN, Schroder FH, van der Kwast TH., 2006

    Journal: Eur Urol
    Reference: Aug;50(2):258-65

    paper

  • 267. Tumour features in the control and screening arm of a randomized trial of prostate cancer.

    Postma R, van Leenders AG, Roobol MJ, Schroder FH, van der Kwast TH., 2006

    Journal: Eur Urol
    Reference: Jul;50(1):70-5

    paper

  • 266. Omtrent de equimolariteit van prostaat-specifiek antigeen.

    Blijenberg BG, Van Zelst BD, Schröder FH, 2005

    Journal: NVKC
    Reference: 30: 42-48

    paper

  • 265. Can PSA density be used to detect prostate cancer?

    van der Kwast TH, Roobol MJ, 2006

    Journal: Nat Clin Pract Urol
    Reference: 3(3):130-131

    paper

  • 264. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC)

    Roemeling S, Roobol MJ, Gosselaar C, Schröder FH, 2006

    Journal: Prostate
    Reference: 66(10): 1076-81

    paper

  • 263. Array-based genomic analysis of screen-detected Gleason score 6 and 7 prostatic adenocarcinomas.

    Postma R, van Marion R, van Duin M, Vissers KJ, Wink JC, Schroder FH, Tanke HJ, Szuhai K, van der Kwast TH, van Dekken H., 2006

    Journal: Anticancer research
    Reference: Mar-Apr;26(2A):1193-200.

  • 262. Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer

    van der Kwast TH, Ciatto S,Martikainen PM, Hoedemaeker R, Laurila M, Pihl C-G,Hugosson J,Neetens I, Nelen V, Di Lollo S, Roobol MJ,Maattanen L, Santonja C, Moss S and Schröder FH, 2006

    Journal: Int J cancer
    Reference: 118, 2538–2542

    paper

  • 261. Prevalence, Treatment Modalities and Prognosis of Familial Prostate Cancer in a Screened Population

    Roemeling S, Roobol MJ, De Vries SH, Gosselaar C, van der Kwast TH, Schröder FH, 2006

    Journal: J Urol
    Reference: 175:1332-1336

    paper

  • 260. Words of wisdom: Comment on Prostate-Specific Antigen Levels in the United States: Implications of Various Definitions for Abnormal.

    Schröder FH, Roobol MJ, 2006

    Journal: Eur Urol
    Reference: 49(2): 412-413

    paper

  • 259. Words of Wisdom: Comment on Incidence and Follow-Up of Patients with Focal Prostate Carcinoma in 2 screening Rounds After an Interval of 4 Years

    Ruutu M, Rannikko A., 2006

    Journal: Eur Urol
    Reference: 49(2):411

    paper

  • 258. Does PSA velocity predict prostate cancer in pre-screened populations?

    Schröder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH, 2006

    Journal: Eur Urol
    Reference: 49(3):460-465

    paper

  • 257. A Comparison of First and Repeat (Four Years Later)Prostate Cancer Screening in a Randomized Cohort of a Symptomatic Men Aged 55-75 Years Using a Biopsy Indication of 3.0 ng/ml (Results of ERSPC,Rotterdam)

    Roobol MJ, Schröder FH, Kranse R, 2006

    Journal: Prostate
    Reference: 66(6):604-612

    paper

  • 256. Screening for Prostate Cancer Without Digital Rectal Examination and Transrectal Ultrasound: Results After Four Years in the European Randomized Study of Screening for Prostate Cancer (ERSPC),Rotterdam

    Gosselaar C, Roobol MJ, Roemeling S, de Vries SH, van der Cruijsen-Koeter IW, van der Kwast TH, Schröder FH, 2006

    Journal: Prostate
    Reference: 66(6):625-631

    paper

  • 255. Prostate cancer: risks and benefits of screening

    Roemeling S, Schröder FH, 2006

    Journal: Nature Clin practice
    Reference: Vol 3 no.1: 4-5

    paper

  • 254. Prostate cancer diagnosis: The impact on patients’ mental health

    Korfage IJ, De Koning HJ, Roobol MJ, Schröder FH, Essink-Bot M, 2006

    Journal: Eur J Cancer
    Reference: Jan;42(2):165-70.

    paper

  • 253. Individualized Screening Interval for Prostate Cancer Based on Prostate-Specific Antigen Level

    Aus G, Damber J-E, Khatami A, Lilja H, Stranne J, Hugosson J., 2005

    Journal: Arch. Intern Med.
    Reference: 165:1857-1861

    paper

  • 252. Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience.

    Van der Kwast TH, Postma R, Hoedemaeker RF, van Leenders GJ, Schröder FH., 2005

    Journal: Can J Urol
    Reference: Jun;12 Suppl 2:16-20

    paper

  • 251. Assessment of Intra-Individual Variation in Prostate-Specific Antigen Levels in a Biennial Randomized Prostate Cancer Screening Program in Sweden

    Bruun L, Becker C, Hugosson J, Lilja H, Christensson A, 2005

    Journal: Prostate
    Reference: 9999

    paper

  • 250. 4-Year Prostate Specific Antigen Progression and Diagnosis of Prostate Cancer in the European Randomized Study of Screening for Prostate Ccancer, Rotterdam

    Schröder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ, 2005

    Journal: J Urol
    Reference: 174:489-494

    paper

  • 249. Comparison of screen detected and clinically diagnosed prostate cancer in the European Randomised study of Screening for Prostate Cancer, section Rotterdam

    van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van dr Kwast TH, Schröder FH, 2005

    Journal: J Urol
    Reference: 174(1): 121-125

    paper

  • 248. Rotterdam Randomized Pilot Studies of Screening for Prostate Cancer — An Overview After 10 Years

    Schröder FH, Roobol MJ, Damhuis RAM, De Koning HJ, Blijneberg BG, Kirkels WJ, Bangma CH, 2005

    Journal: JNCI
    Reference: 97(9): 696

    paper

  • 247. “Additional use of [-2] precursor prostate specific antigen and “”benign”” PSA at diagnosis in screen-detected prostate cancer”

    De Vries SH, Raaijmakers R, Blijenberg BG, Mikolajczyk SD, Rittenhouse HG, Schröder FH., 2005

    Journal: Urology
    Reference: 65:926-930

    paper

  • 246. Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men

    Postma R, Schröder FH, van der Kwast TH, 2005

    Journal: Urology
    Reference: 65: 745-749

    paper

  • 245. Is additional testing necessarry in men with prostate-specific antigen levels of 1.0 ng/ml or less in a population based screening setting? (ERSPC, section Rotterdam)

    Roobol MJ, Roobol DW, Schröder FH, 2005

    Journal: Urology
    Reference: 65(2):343-346

    paper

  • 244. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC)

    Schröder FH, 2005

    Journal: Can J Urol
    Reference: 12(1): 2463-2467

    paper

  • 243. Screening for prostate cancer.

    Postma R, Schröder FH, 2005

    Journal: Eur J Cancer
    Reference: 41:825-833

    paper

  • 242. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.

    Ito K, Raaijmakers R, Roobol M, Wildhagen M, Yamanaka H, Schröder FH., 2005

    Journal: Cancer
    Reference: Jan 15;103(2):242-50

    paper

  • 241. Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994).

    Ciatto S, Gervasi G, Bonardi R, Frullini P, Zendron P, Lombardi G, Crocetti E, Zappa M., 2005

    Journal: Eur J Cancer
    Reference: 41: 411-415

    paper

  • 240. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.

    Postma R, de Vries SH, Roobol MJ, Wildhagen MF, Schröder FH, van der Kwast TH., 2005

    Journal: Cancer
    Reference: 103 (4): 708-716

    paper

  • 239. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?

    Gosselaar C, Roobol MJ, Schröder FH, 2005

    Journal: BJUI
    Reference: 95: 231-237

    paper

  • 238. Association of human papillomavirus with prostate cancer: analysis of a consecutive series of prostate biopsies.

    Carozzi F, Lombardi FC, Zendron P, Confortini M, Sani C, Bisanzi S, Pontenani G, Ciatto S., 2004

    Journal: Int. J. Biol Markers
    Reference: 19(4):257-61

    paper

  • 237. Population based screening for prostate cancer:the pathology of early detected tumors. Part I. (Dutch with english summary)

    Hoedemaeker RF, van der Kwast TH, Schröder FH, 2004

    Journal: NTvU
    Reference: Nov;4

  • 236. Watchful waiting versus expectant management at prostatic carcinoma (Dutch with english summary)

    de Vries SH, Bangma CH, Schröder FH, 2004

    Journal: NTvU
    Reference: Nov;4

  • 235. Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy.

    de Vries SH, Raaijmakers R, Kranse R, Blijenberg BG, Schröder FH., 2004

    Journal: J Urol
    Reference: Dec;172(6 Pt 1):2193-6

    paper

  • 234. Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias?

    Otto SJ, Schröder FH, de Koning HJ, 2004

    Journal: J Mec Screen
    Reference: 11(2):89-92

  • 233. Biopsy technique and biopsy schemes for a first series of prostatic biopsies

    Villers A, Mouton D, Rebillard X, Chautard D, Ruffion A, Staerman F, Cornud F, 2004

    Journal: Prog Urol.
    Reference: 14(2):144-53

  • 232. Predictors of random sextant biopsy outcome in screened men with PSA > 4 ng/mL and a negative sextant biopsy at previous screening. Experience in a population-based screening program in Florence.

    Ciatto S, Lombardi C, Rubeca T, Zappa M, 2004

    Journal: Int J Biol Markers
    Reference: 19(2):89-92

  • 231. Detection characteristics in randomized prostate screening

    Schröder FH, Roobol MJ, 2004

    Journal: Clin Can Res
    Reference: 10:5641-5642

    paper

  • 230. Prostate volume ultrasonography: the influence of transabdominal versus transrectal approach, device type and operator

    Huang Foen Chung JWNC, De Vries SH, raaijmakers R, postma R, Bosch JLHR, van Mastrigt R, 2004

    Journal: Eur Urol
    Reference: 46:352-356

    paper

  • 229. Circulating free insulin-like growth factor (IGF)-I, Total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population based screening with a 4-year interval

    Janssen JAMJL, Wildhagen MF, Ito K, Blijenberg BG, van Schaik RHN, Roobol MJ, Pols HAP, Lamberts SWJ, Schröder FH, 2004

    Journal: J Clin Endocr & meta
    Reference: 89(9):4391-4396

    paper

  • 228. Prostate cancer detection in the prostate specific antigen range of 2.0 – 3.9 ng/ml, value of percent free PSA on tumor detection and tumor aggressiveness

    Raaijmakers R, Blijenberg BG, Finlay JA, Rittenhouse HG, Wildhagen MF, Roobol MJ, Schröder FH, 2004

    Journal: J Urol
    Reference: 171:2245-2249

    paper

  • 227. Second round results of the Finnish population-based prostate cancer screening trial.

    Makinen T, Tammela TL, Stenman UH, Maattanen L, Aro J, Juusela H, Martikainen P, Hakama M, Auvinen A., 2004

    Journal: Clin cancer Res
    Reference: 10:2231-2236

    paper

  • 226. Lesions predictive for prostate cancer in a screened population: first and second screening round findings

    Postma R, Roobol M, Schröder FH, van der Kwast TH, 2004

    Journal: Prostate
    Reference: 61:260-266

    paper

  • 225. Screening for prostate cancer: Results of a prospective trial in Canton Aargau, Switzerland.

    Kwiatkowski M, Huber A, Moschopulos M, Lehmann K, Wernli M, Häfeli A, Recker F., 2004

    Journal: Swiss Med Wkly
    Reference: 134:580-585

    paper

  • 224. Free to total PSA ratio is not a reliable predictor of prostate biopsy outcome.

    Ciatto S, Rubeca T, Confortini M, Pontenani G, Lombardi C, Zendron P, Di Lollo S, Crocetti E., 2004

    Journal: Tumori
    Reference: May-Jun;90(3):324-7

  • 223. De rol van familiaire prostaatkanker bij vroegopsporing. Resultaten van het nederlandse deel van de ERSPC

    Roobol MJ, 2004

    Journal: IKR bulletin
    Reference: Jan: 42-44

  • 222. Leadtime associated with screening for prostate cancer

    Törnblom M, Eriksson H, Franzen S, Gustafsson O, Lilja H, Norming U, Hugosson J, 2004

    Journal: Int. J. Cancer
    Reference: 108:122-129

    paper

  • 221. Prostate cancer detection and tumor characteristics in men with multiple biopsy sessions

    Lujan M, Paez A, Santonja C, Pascual T, Fernandez I, Berenguer A, 2004

    Journal: Pros. Cancer and Pros. Dis
    Reference: 14-08-03

    paper

  • 220. Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial

    Auvinen A, Määttänen L, Finne P, Stenman U-H, Aro J, Juusela H, Ranniko S, Tammela TLJ, Hakama M, 2004

    Journal: Int. J Cancer
    Reference: 111:940-943

    paper

  • 219. Prostate Cancer Detection is Also Relevant in LowProstate Specific Antigen Ranges

    Lujan M, Paez A, Miravalles E, Fernandez I, Llanes L, Berenguer A, 2004

    Journal: Eur Urol
    Reference: 45:155–159

    paper

← PreviousNext →